Who are IPI1/NIVO3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IPI3/NIVO1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ipi1-nivo3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IPI1/NIVO3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IPI1/NIVO3 (IPI1/NIVO3) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor). Area: Oncology.

phase 3 Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor) ICOS and PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IPI1/NIVO3 (IPI1/NIVO3) — Vastra Gotaland Region. IPI1/NIVO3 is a combination of an inducible T-cell co-stimulator (ICOS) agonist and a PD-1 inhibitor that enhances anti-tumor immune responses by activating T cells while removing inhibitory checkpoint signals.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IPI1/NIVO3 TARGET	IPI1/NIVO3	Vastra Gotaland Region	phase 3	Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor)	ICOS and PD-1
IPI3/NIVO1	IPI3/NIVO1	Vastra Gotaland Region	phase 3	ICOS agonist + PD-1 inhibitor combination	ICOS and PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor) class)

Vastra Gotaland Region · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IPI1/NIVO3 — Competitive Intelligence Brief. https://druglandscape.com/ci/ipi1-nivo3. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing